IMDZ Immune Design Corp.

10.50
+0.15  (1%)
Previous Close 10.35
Open 10.35
Price To book 3.66
Market Cap 269007186
Shares 25,619,732
Volume 85,116
Short Ratio 10.13
Av. Daily Volume 176,997

SEC filingsSee all SEC filings

  1. 8-K - Current report 171075101
  2. 8-K - Current report 171061726
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000432
  4. 8-K - Current report 17999982
  5. 8-K - Current report 17945341

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data at ASCO 2017 (June 2, 2017). Also due at ASH 2017.
G100
Follicular non-Hodgkin Lymphoma - cancer
Phase 2 data at ASCO 2017 with further interim analysis at ESMO September 2017. PFS 2.6 months, Disease Control Rate 61%.
CMB305
Soft tissue sarcomas

SEC Filings

  1. 8-K - Current report 171075101
  2. 8-K - Current report 171061726
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171000432
  4. 8-K - Current report 17999982
  5. 8-K - Current report 17945341
  6. 424B5 - Prospectus [Rule 424(b)(5)] 17945304
  7. CT ORDER - Confidential treatment order 17940667
  8. 8-K - Current report 17913845
  9. 8-K - Current report 17852258
  10. S-8 - Securities to be offered to employees in employee benefit plans 17829442